- Home
- SOHO vs MTVA Comparison
SOHO vs MTVA Comparison
Compare SOHO & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOHO
- MTVA
- Stock Information
- Founded
- SOHO 2004
- MTVA 2014
- Country
- SOHO United States
- MTVA United States
- Employees
- SOHO N/A
- MTVA N/A
- Industry
- SOHO Real Estate Investment Trusts
- MTVA
- Sector
- SOHO Real Estate
- MTVA
- Exchange
- SOHO Nasdaq
- MTVA NYSE
- Market Cap
- SOHO 16.3M
- MTVA 13.6M
- IPO Year
- SOHO 2004
- MTVA N/A
- Fundamental
- Price
- SOHO $0.74
- MTVA $0.81
- Analyst Decision
- SOHO Hold
- MTVA Strong Buy
- Analyst Count
- SOHO 1
- MTVA 1
- Target Price
- SOHO $1.50
- MTVA $12.00
- AVG Volume (30 Days)
- SOHO 52.3K
- MTVA 1.4M
- Earning Date
- SOHO 05-13-2025
- MTVA 05-08-2025
- Dividend Yield
- SOHO N/A
- MTVA N/A
- EPS Growth
- SOHO N/A
- MTVA N/A
- EPS
- SOHO N/A
- MTVA N/A
- Revenue
- SOHO $180,394,287.00
- MTVA N/A
- Revenue This Year
- SOHO $13.93
- MTVA N/A
- Revenue Next Year
- SOHO N/A
- MTVA N/A
- P/E Ratio
- SOHO N/A
- MTVA N/A
- Revenue Growth
- SOHO 3.91
- MTVA N/A
- 52 Week Low
- SOHO $0.59
- MTVA $0.71
- 52 Week High
- SOHO $1.54
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- SOHO 54.72
- MTVA N/A
- Support Level
- SOHO $0.70
- MTVA N/A
- Resistance Level
- SOHO $0.79
- MTVA N/A
- Average True Range (ATR)
- SOHO 0.07
- MTVA 0.00
- MACD
- SOHO 0.01
- MTVA 0.00
- Stochastic Oscillator
- SOHO 72.90
- MTVA 0.00
About SOHO Sotherly Hotels Inc.
Sotherly Hotels Inc is engaged in Hotel operations. The company is a self-managed and self-administered lodging real estate investment trust that was formed to own, acquire, renovate, and reposition full-service, upscale, and upper-upscale hotel properties located in primary markets in the mid-Atlantic and southern United States. It generates revenue through the rooms, food, beverage, and other services. Geographically, the group has its presence in the regions of Florida, Georgia, Indiana, Maryland, North Carolina, Pennsylvania, Texas, and Virginia.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.